Multiple Chinese developers of antibody-drug conjugates (ADCs) are now turning their focus to bispecific candidates based on different target combinations as they look to diversify their expertise in the fast-growing field.
The fresh drive for bispecifics has quickened pace over the past few months on the back of a huge licensing deal worth up to $8.4bn for the EGFR x HER3-targeting...
Key Takeaways
-
Chinese biotechs' fresh drive to develop bispecific ADCs has quickened on the back of an up to $8.4bn licensing deal with BMS for...